
	<!DOCTYPE html>
	<html>
		<head>
			<title>【光大医药】创新药回暖，推荐荣昌生物、康诺亚！</title>
			<meta charset="utf-8" />
		</head>
		<body>
			<div class="note-wrapper">
				<h1>【光大医药】创新药回暖，推荐荣昌生物、康诺亚！</h1>
				<button class="btn btn-primary"><a href="../index.html">返回主页</a></button><br><br>
				【光大医药】创新药回暖，推荐荣昌生物、康诺亚！<br>创新药板块经过长时间回调，很多优质资产进入具有性价比的估值底部区间，近期行情开始回暖，迎来布局良机。<br>1）市场风险偏好已达10年最低水平，或将迎来创新药大行情<br>医药生物行业的股权风险溢价（ERP）自2021年初以来持续上升，截至2022年6月初已经达到10年来历史最高值，意味着市场对医药的风险偏好持续降低至历史最低值。当市场风险偏好开始转向上升时，资金可能更乐于流向风险和潜在收益都较高的创新药板块，带来较好的创新药股价表现。<br>2）疫情影响弱化，销售与临床工作逐步恢复正常<br>2022年以来各地散发的新冠疫情对于创新药的销售和临床试验工作产生一定影响，随着疫情逐步得到控制，社会经济活动恢复正常，药品终端销售和临床试验入组等工作逐步回到正轨，创新药行业恢复健康良性发展态势。<br>3）政策导向进入提质阶段，创新药从同质化内卷走向临床价值决胜<br>○国家医保局在2021.11印发了《DRG/DIP支付方式改革三年行动计划》，我们预计支付方式改革可能会引发医疗终端药物临床价值的优胜劣汰，临床价值将成为药物商业价值的关键决定因素。<br>○药监局药审中心则在2021.11发布《以临床价值为导向的抗肿瘤药物临床研发指导原则》，标志着me-too创新药的时代红利结束。<br>○2022年7月13日，北京市医疗保障局印发《CHS-DRG付费新药新技术除外支付管理办法的通知（试行）》，高临床价值创新药将得到更好的商业化环境。<br>上个时代的大量me-too创新药带来的同质化内卷走向尾声，终端竞争将走向以临床价值决胜，高临床价值药物将获得更好的商业环境。<br>当前重点推荐荣昌生物、康诺亚生物！<br>①荣昌生物：核心产品维迪西妥单抗和泰它西普商业化进展顺利，并且适应症均针对临床相对空白的利基市场，具有差异化的独特临床价值，高度契合政策监管的导向。维迪西妥单抗以26亿美金授权Seagen，得到全球ADC龙头企业的认可；泰它西普的海外临床有序推进。<br>②康诺亚：核心产品抗IL-4Rα单抗CM310国内临床进度领先，特应性皮炎III期临床于2022.4入组首例受试者，2022.6拟纳入突破性疗法目录。CM310对标产品Dupixent是赛诺菲当前王牌产品，2021年销售额达52.49亿欧元，同比+52.7%。公司对过敏性疾病的大赛道战略布局具有前瞻性，有望充分受益于过敏性疾病的时代红利。<br><br>#文字纪要#
				<br><br><button class="btn btn-primary"><a href="../index.html">返回主页</a></button>
	
			</div>
			<script type="text/javascript">
				(function() {
	
		var doc_ols = document.getElementsByTagName("ol");
	
		for ( i=0; i<doc_ols.length; i++) {
	
			var ol_start = doc_ols[i].getAttribute("start") - 1;
			doc_ols[i].setAttribute("style", "counter-reset:ol_counter " + ol_start + ";");
	
		}
	
	})();
	
			</script>
			<style>
				html,body,div,span,applet,object,iframe,h1,h2,h3,h4,h5,h6,p,blockquote,pre,a,abbr,acronym,address,big,cite,code,del,dfn,em,img,ins,kbd,q,s,samp,small,strike,strong,sub,sup,tt,var,b,u,i,center,dl,dt,dd,ol,ul,li,fieldset,form,label,legend,table,caption,tbody,tfoot,thead,tr,th,td,article,aside,canvas,details,embed,figure,figcaption,footer,header,hgroup,menu,nav,output,ruby,section,summary,time,mark,audio,video{margin:0;padding:0;border:0;font:inherit;font-size:100%;vertical-align:baseline}html{line-height:1}ol,ul{list-style:none}table{border-collapse:collapse;border-spacing:0}caption,th,td{text-align:left;font-weight:normal;vertical-align:middle}q,blockquote{quotes:none}q:before,q:after,blockquote:before,blockquote:after{content:"";content:none}a img{border:none}article,aside,details,figcaption,figure,footer,header,hgroup,main,menu,nav,section,summary{display:block}*{-moz-box-sizing:border-box;-webkit-box-sizing:border-box;box-sizing:border-box}html{font-size:87.5%;line-height:1.57143em}html{font-size:14px;line-height:1.6em;-webkit-text-size-adjust:100%}body{background:#fcfcfc;color:#545454;text-rendering:optimizeLegibility;font-family:"AvenirNext-Regular"}a{color:#de4c4f;text-decoration:none}h1{font-family:"AvenirNext-Medium";color:#333;font-size:1.6em;line-height:1.3em;margin-bottom:.78571em}h2{font-family:"AvenirNext-Medium";color:#333;font-size:1.3em;line-height:1em;margin-bottom:.62857em}h3{font-family:"AvenirNext-Medium";color:#333;font-size:1.15em;line-height:1em;margin-bottom:.47143em}p{margin-bottom:1.57143em;hyphens:auto}hr{height:1px;border:0;background-color:#dedede;margin:-1px auto 1.57143em auto}ul,ol{margin-bottom:.31429em}ul ul,ul ol,ol ul,ol ol{margin-bottom:0px}ol{counter-reset:ol_counter}ol li:before{content:counter(ol_counter) ".";counter-increment:ol_counter;color:#e06e73;text-align:right;display:inline-block;min-width:1em;margin-right:0.5em}b,strong{font-family:"AvenirNext-Bold"}i,em{font-family:"AvenirNext-Italic"}code{font-family:"Menlo-Regular"}.text-overflow-ellipsis{overflow:hidden;text-overflow:ellipsis;white-space:nowrap}.sf_code_string,.sf_code_selector,.sf_code_attr-name,.sf_code_char,.sf_code_builtin,.sf_code_inserted{color:#D33905}.sf_code_comment,.sf_code_prolog,.sf_code_doctype,.sf_code_cdata{color:#838383}.sf_code_number,.sf_code_boolean{color:#0E73A2}.sf_code_keyword,.sf_code_atrule,.sf_code_rule,.sf_code_attr-value,.sf_code_function,.sf_code_class-name,.sf_code_class,.sf_code_regex,.sf_code_important,.sf_code_variable,.sf_code_interpolation{color:#0E73A2}.sf_code_property,.sf_code_tag,.sf_code_constant,.sf_code_symbol,.sf_code_deleted{color:#1B00CE}.sf_code_macro,.sf_code_entity,.sf_code_operator,.sf_code_url{color:#920448}.note-wrapper{max-width:46em;margin:0px auto;padding:1.57143em 3.14286em}.note-wrapper.spotlight-preview{overflow-x:hidden}u{text-decoration:none;background-image:linear-gradient(to bottom, rgba(0,0,0,0) 50%,#e06e73 50%);background-repeat:repeat-x;background-size:2px 2px;background-position:0 1.05em}s{color:#878787}p{margin-bottom:0.1em}hr{margin-bottom:0.7em;margin-top:0.7em}ul li{text-indent:-0.35em}ul li:before{content:"•";color:#e06e73;display:inline-block;margin-right:0.3em}ul ul{margin-left:1.25714em}ol li{text-indent:-1.45em}ol ol{margin-left:1.25714em}blockquote{display:block;margin-left:-1em;padding-left:0.8em;border-left:0.2em solid #e06e73}.todo-list ul{margin-left:1.88571em}.todo-list li{text-indent:-1.75em}.todo-list li:before{content:"";display:static;margin-right:0px}.todo-checkbox{text-indent:-1.7em}.todo-checkbox svg{margin-right:0.3em;position:relative;top:0.2em}.todo-checkbox svg #check{display:none}.todo-checkbox.todo-checked #check{display:inline}.todo-checkbox.todo-checked+.todo-text{text-decoration:line-through;color:#878787}.code-inline{display:inline;background:white;border:solid 1px #dedede;padding:0.2em 0.5em;font-size:0.9em}.code-multiline{display:block;background:white;border:solid 1px #dedede;padding:0.7em 1em;font-size:0.9em;overflow-x:auto}.hashtag{display:inline-block;color:white;background:#b8bfc2;padding:0.0em 0.5em;border-radius:1em;text-indent:0}.hashtag a{color:#fff}.address a{color:#545454;background-image:linear-gradient(to bottom, rgba(0,0,0,0) 50%,#0da35e 50%);background-repeat:repeat-x;background-size:2px 2px;background-position:0 1.05em}.address svg{position:relative;top:0.2em;display:inline-block;margin-right:0.2em}.color-preview{display:inline-block;width:1em;height:1em;border:solid 1px rgba(0,0,0,0.3);border-radius:50%;margin-right:0.1em;position:relative;top:0.2em;white-space:nowrap}.color-code{margin-right:0.2em;font-family:"Menlo-Regular";font-size:0.9em}.color-hash{opacity:0.4}.ordered-list-number{color:#e06e73;text-align:right;display:inline-block;min-width:1em}.arrow svg{position:relative;top:0.08em;display:inline-block;margin-right:0.15em;margin-left:0.15em}.arrow svg #rod{stroke:#545454}.arrow svg #point{fill:#545454}mark{color:inherit;display:inline;padding:0.2em 0.5em;background-color:#fcffc0}img{max-width:100%;height:auto}
			</style>
		</body>
	</html>
	